Gadolinium-based contrast agents (GBCAs) used in MRI and angiography contain a chelated form of the toxic heavy metal that was assumed to clear the body shortly after intravenous administration. [1] ...

Patients with chronic kidney disease (CKD) who receive a gadolinium-based contrast agent (GBCA) have a low risk of developing nephrogenic systemic fibrosis (NSF), a systematic review and meta-analysis ...

New research suggests that MRI with contrast may create nanoparticles that infiltrate your tissues. The research is preliminary, and more work needs to be done. Doctors stress that MRI with contrast ...

A new study has found why MRI scans may leave harmful metals behind in a person's body. The University of New Mexico (UNM) study explored health risks caused by toxic rare earth metal gadolinium, ...

Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with the highest relaxivity, in comparison to other availab ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...